Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Kent State University maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The prosecution data reveals 1 pending office action currently active at the USPTO. This matter is assigned to 1 distinct examiner, REYNOLDS, FRED H, who is the only examiner listed for the company. The portfolio is further concentrated within a distinct art unit, indicating a specific technical focus for the current filings. REYNOLDS, FRED H is identified as the busiest examiner, with the busiest examiner pending action.
For practitioners, the involvement of a distinct examiner and a distinct art unit suggests a highly localized prosecution environment. The presence of 1 pending office action allows for a focused legal strategy tailored to the specific tendencies of REYNOLDS, FRED H. Because the busiest examiner pending count is not spread across multiple individuals, the prosecution remains centralized. This focus within the Biotechnology & Pharmaceuticals sector allows for a consistent approach to navigating the assigned art unit and managing pharmaceutical patent claims.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17617978 | COMPOSITIONS TARGETING SPERM CALCINEURIN | REYNOLDS, FRED H | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17617978 | COMPOSITIONS TARGETING SPERM CALCINEURIN | REYNOLDS, FRED H | 14d |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17617978 | COMPOSITIONS TARGETING SPERM CALCINEURIN | REYNOLDS, FRED H | 1658 | §102§103§112 | Non-Final OA | 14d | Pending | Dec 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial